Lisa R. Sammaritano, MD
Dr. Lisa Sammaritano joined Hospital for Special Surgery in 1988, when she began her fellowship in rheumatic diseases. She maintains a busy clinical practice and participates in clinical research geared towards patients with Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibodies. She has a particular interest and expertise in reproductive issues in rheumatic disease patients, including contraception and pregnancy.
Associate Attending Physician, Hospital for Special Surgery
Associate Professor of Clinical Medicine, Weill Cornell Medical College
Systemic Lupus Erythematosus (SLE)
Pregnancy and Rheumatic Diseases
Hormones in Rheumatic Diseases
Alpha Omega Alpha Medical Honor Society
Phi Beta Kappa Honor Society
Blue Cross HMO POS
Blue Cross PPO
If your particular insurance plan is not listed, you may still have coverage subject to the availability of 'out-of-network' benefits. Please do not hesitate to contact our office if you have questions regarding your insurance coverage.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of March 26, 2015, Dr. Sammaritano reported no financial interest relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
BA, University of Pennsylvania, Philadelphia, Pennsylvania, 1981
MD, Weill Cornell Medical College, New York, 1985
Weill Cornell Medical College, Internal Medicine, 1985-88
Weill Cornell Medical College, Rheumatology, 1988-91
Internal Medicine, 1988
For more publications, please see the PubMed listing.
Antiphospholipid antibodies (aPL) are associated with a clinical syndrome which includes recurrent arterial and venous thromboses, recurrent fetal loss, thrombocytopenia and other complications. The mechanism of action of these autoantibodies has not been well defined. It is clear that most aPL bind to a cryptic epitope on a normal plasma glycoprotein, Beta 2-glycoprotein I, when this glycoprotein is bound to phospholipid.
Our recent work has shown activation of cultured human vein endothelial cells (HUVEC) by IgG from patients with anticardiolipin antibodies (aCL). Incubation with aCL IgG produced a 7-fold increase in monocyte adhesion compared with incubation with IgG from normal controls. Immunofluorescent microscopy demonstrated increased expression of cell adhesion molecules including E selectin, VCAM-1, and I CAM - 1.
We have also investigated possible contributors to aPL risk, or "second hit" factors. We have identified presence of IgG2 subclass of aCL to be associated with clinical risk of thrombosis. Presence of factor V Leiden is more common in aCL patients with as compared to without thrombosis. Finally, we continue to investigate other potential genetic or environmental risk factors, including FcRIIa allelic variation and homcysteinemia.
The safety of exogenous estrogens in systemic lupus has been widely questioned, with several case reports and one retrospective study suggesting an increased risk of flare associated with oral contraceptive use. Because of the potential benefits of oral contraceptives and hormone replacement therapy, we are conducting a nationwide multicenter randomized placebo-controlled double blind study to evaluate the safety of these preparations in patients with stable or inactive SLE. Hospital for Special Surgery is one of 5 centers participating in this NIH funded project, which may change practice patterns if safety of estrogens is shown.